Mergers & Acquisitions ·
Barinthus Biotherapeutics plc completed a merger transaction on September 9, 2026, pursuant to a court-sanctioned…
BRNSBarinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc completed a merger transaction on September 9, 2026, pursuant to a court-sanctioned scheme of arrangement. Beacon Topco, Inc. acquired all issued and to be issued share capital of Barinthus, making it a wholly-owned subsidiary. Existing shareholders received 0.111 shares of Topco common stock for each ordinary share held. The company's American Depositary Shares were delisted from Nasdaq effective September 9, 2026, and the deposit agreement was terminated. Outstanding equity awards were converted into rights to receive Topco common stock on substantially similar terms. Barinthus Biotherapeutics plc operates in the biotechnology industry, focusing on developing therapies for neurological diseases.